FDA Naming Delay Cut Short Exclusivity, Drugmaker Says
The U.S. Food and Drug Administration must revise the approval date and extend the exclusivity for anti-side-effect medication Fusilev to account for regulatory delays in clearing a brand name for the...To view the full article, register now.
Already a subscriber? Click here to view full article